Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Adaptin Bio Inc's Competitiveness

Name: Adaptin Bio Inc Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Adaptin Bio Inc (APTN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2026

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/APTN/competitors

https://api.csimarket.com/api/v1/companies/APTN/relationships

https://api.csimarket.com/api/v1/companies/APTN/similar

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

What's Included in the Financial API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Adaptin Bio Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
ADAPTIN BIO, INC.	-	-	-	Yes
High-Confidence Competitors (6)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

APTN Stock Performance relative to its Competitors

APTN Competitors (weighted) Percent change over the selected range

Adaptin Bio Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

High-Confidence
(2 of 5)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
ADAPTIN BIO, INC.	-	-
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (5)	40.4%	63.2%
Similar-Size Competitors (0)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Adaptin Bio Inc's competitor groups requires a Commercial License.

Unlock Full Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

APTN Stock Performance relative to High-Confidence Competitors

APTN High-Confidence Competitors (equal-weighted, 7) Percent change over the selected range

Adaptin Bio Inc's Comment on Competition and Industry Peers

The pharmaceutical industry is characterized by intense and rapidly evolving competition focused on developing new technologies and proprietary products, particularly in areas of high unmet medical need targeted by the company. Competitors include major and specialty pharmaceutical and biotechnology firms worldwide, many with greater resources and capital access. Specifically, Context Therapeutics, Vir Biotechnology, and Janux Therapeutics, Inc. are researching immune cell engagers with different targets. Amgen Inc. and Genentech, Inc., a wholly owned subsidiary of Roche Holding AG, have programs involving a form of EGFRvIII x CD3 bispecific T cell engager, although neither combines these with activated T cells. The company's success depends in part on its ability to develop safe and effective product candidates that address unmet patient needs ahead of competitors.

Competitor data is not yet available for Adaptin Bio Inc.

Adaptin Bio Inc's Competitors Named by the Company

Competitive relationships identified from Adaptin Bio Inc reports and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
Janux Therapeutics, Inc.	Company report	85%	2022 to 2026	3
Context Therapeutics	Company report	85%	2022 to 2026	3
Genentech, Inc.	Company report	85%	2022 to 2026	3
Amgen Inc.	Company report	85%	2022 to 2026	3
Vir Biotechnology	Company report	85%	2022 to 2026	3
Affimed N.V.	Company report	85%	2022 to 2026	3
NexImmune, Inc.	Company report	85%	2022 to 2026	3

Competitor Evidence Detail

Company report basis, confidence, active dates and source counts for Adaptin Bio Inc's named competitors require a Commercial License.

Unlock Full Access

Methodology: relationships are extracted from Adaptin Bio Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.